“…In some trials, significant toxicities were reported (16,17,26), although in other studies, the same combinations appeared well-tolerated with encouraging results (11,18,19,(21)(22)(23)(24)(25)27). Three categories of combinations were used in the trials: (1) bevacizumab in combination with erlotinib and chemotherapy/ chemoradiotherapy (16,23,27); (2) bevacizumab in combination with cetuximab and chemotherapy/chemoradiotherapy (17,18,21) and ( 3) bevacizumab in combination with chemotherapy or chemoradiotherapy (11,19,20,22,24,26). Significant toxicities, such as a perforation, fistula, diarrhoea, mucositis, dysphagia, haemorrhage and hematologic toxicity, were reported in one trial from all of these treatment combinations, and no further trials were recommended (16,17,26).…”